Dr. Jack Cush reviews the news and major articles from this week, including FDA safety warnings, reports from AAD, PsA trials.
Dr. John Cush RheumNow
5 months 3 weeks ago
Advanced Practice Rheum: Rheumatoid & Inflammation Testing
In this review, we'll be talking about labs, inflammation, and tests for rheumatoid arthritis.
https://t.co/UbEoBz37hT https://t.co/V9WzfRtbFQ
Dr. John Cush RheumNow
5 months 3 weeks ago
Ixekizumab With Tirzepatide Efficacy in Obese Psoriatic Arthritis
The TOGETHER-PsA trial has demonstrated the efficacy and safety of ixekizumab (IXE) administered with tirzepatide (TZP) in adult active psoriatic arthritis (PsA) patients who were overweight or obese. https://t.co/KFwfi9FaAh
The Journal of Neurology has posted a review and update of Primary CNS vasculitis (PCNSV), also termed primary angiitis of the CNS (PACNS). PCNSV is rare, potentially fatal, and highly treatable, making timely recognition and accurate diagnosis critical.
Dr. John Cush RheumNow
5 months 4 weeks ago
AAD 2026 Annual Mtg presents new data on another TYK2 inhibitor. In 2 phase 3 RCTs (ONWARD1 ONWARD2) envudeucitinib was superior to placebo & apremilast in 1700 plaque psoriasis pts https://t.co/DPlzDw5m7N
Dr. John Cush RheumNow
5 months 4 weeks ago
What's it like to have #RA? PATTY "To find patients or doctors who can talk intelligently about RA is a welcomed relief. However, I prefer that those around me not know about me and my RA. I hope they don’t notice the changes in my hands or shoes or that I cannot wear my usual https://t.co/OQbXJrcyPp
Dr. John Cush RheumNow
5 months 4 weeks ago
After hours EHR catchup has been coined "Pajama time" by residents & physicians & contributes to burnout. Survey 9,731 YR 2 Family Med residents- spend 3+ hrs/d after wk on ambulatory EHRs. Pajama time assoc w/ less knowledge, professional satisfaction, more burnout. https://t.co/QSR7VM2T7u
Dr. John Cush RheumNow
5 months 4 weeks ago
Brepocitinib in Dermatomyositis
The NEJM reports that brepocitinib, an oral TYK2–JAK1 inhibitor, was studied in a phase 3 trial of refractory dermatomyositis (DM) patients and shown to have significant benefits at the higher dose.
https://t.co/YNxrVTIubb https://t.co/uFY3kMOvui
Dr. John Cush RheumNow
5 months 4 weeks ago
AFFINITY Study - Combination Biologic Therapy in PsA
A pilot trial assessed the efficacy and safety of the guselkumab+golimumab (COMBO) combination versus GUS monotherapy in active PsA (failing a prior tumor necrosis factor inhibitor (TNFi-IR) and showed superiority in ACR 50 https://t.co/f2CB8FnZMB
Dr. John Cush RheumNow
5 months 4 weeks ago
FDA has issued a drug safety warning for avacopan (Tavneos), dentifying 76 cases of drug-induced liver injury, including 7 cases of rare vanishing bile duct syndrome (VBDS). There were 8 deaths https://t.co/WkBhs1rNpf https://t.co/ZXdHsAJUOQ
Yesterday the FDA issued a Drug Safety Communication alerting patients and health care professionals about postmarketing identification of serious (drug induced) liver injury, including fatal cases, associated with the use of avacopan (Tavneos) in patients with ANCA- associated vasculitis.
Dr. John Cush RheumNow
5 months 4 weeks ago
The Mucosal Hypothesis of Rheumatoid Arthritis. Dr. Kristin Demoruelle
In this https://t.co/4UQlqwujiR 2026 podcast, Dr. Kristin Demoruelle explores the mucosal origins of RA and its implications.
🎧 Listen here: https://t.co/QxldIpYQC8
#Rheumatology #Autoimmunity #RNL2026 https://t.co/nz2dbwll14
Dr. John Cush RheumNow
5 months 4 weeks ago
DERM on RheumNow PODCAST (March 2026)
https://t.co/OGl34cH6z5 https://t.co/l7v1Xktl8r
RA-ILD represents the most severe extra-articular manifestation of rheumatoid arthritis, affecting an estimated 1% of the adult population in the US and Northern Europe. Prevalence estimates vary widely (up to 58%), reflecting different diagnostic criteria, imaging modalities, and study populations.
